LivaNova (LIVN) Stock Rating Upgraded by BidaskClub

LivaNova (NASDAQ:LIVN) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Wednesday.

Other analysts also recently issued research reports about the company. Zacks Investment Research upgraded LivaNova from a “hold” rating to a “buy” rating and set a $89.00 price target for the company in a research note on Thursday, November 9th. BTIG Research reissued a “hold” rating on shares of LivaNova in a research report on Tuesday, November 7th. Piper Jaffray Companies reissued a “buy” rating and set a $85.00 price objective on shares of LivaNova in a research report on Friday, November 3rd. Canaccord Genuity reissued a “hold” rating and set a $76.00 price objective on shares of LivaNova in a research report on Tuesday, December 5th. Finally, ValuEngine raised LivaNova from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. LivaNova currently has an average rating of “Hold” and an average price target of $79.71.

Shares of LivaNova (NASDAQ:LIVN) opened at $85.91 on Wednesday. The stock has a market capitalization of $4,148.12, a PE ratio of 24.80, a PEG ratio of 2.55 and a beta of 0.83. LivaNova has a 52 week low of $46.34 and a 52 week high of $88.56. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.42 and a current ratio of 2.03.

In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $80.80, for a total transaction of $80,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Hugh M. Morrison sold 1,830 shares of the business’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $88.00, for a total value of $161,040.00. The disclosure for this sale can be found here. Insiders have sold a total of 4,830 shares of company stock valued at $407,310 in the last three months. 0.28% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vaughan Nelson Investment Management L.P. acquired a new position in LivaNova in the 4th quarter valued at approximately $55,467,000. Hermes Investment Management Ltd. acquired a new position in LivaNova in the 4th quarter valued at approximately $39,663,000. Dimensional Fund Advisors LP raised its holdings in LivaNova by 42.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,317,901 shares of the company’s stock valued at $92,331,000 after acquiring an additional 395,672 shares in the last quarter. American Century Companies Inc. raised its holdings in LivaNova by 126.7% in the 3rd quarter. American Century Companies Inc. now owns 391,099 shares of the company’s stock valued at $27,400,000 after acquiring an additional 218,599 shares in the last quarter. Finally, NWQ Investment Management Company LLC raised its holdings in LivaNova by 71.2% in the 3rd quarter. NWQ Investment Management Company LLC now owns 500,594 shares of the company’s stock valued at $35,072,000 after acquiring an additional 208,264 shares in the last quarter. 87.06% of the stock is owned by institutional investors and hedge funds.

WARNING: “LivaNova (LIVN) Stock Rating Upgraded by BidaskClub” was posted by Week Herald and is the property of of Week Herald. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://weekherald.com/2018/02/23/livanova-livn-stock-rating-upgraded-by-bidaskclub.html.

About LivaNova

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Analyst Recommendations for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply